C4 Therapeutics (CCCC) Total Liabilities (2019 - 2026)

C4 Therapeutics' Total Liabilities history runs 8 years deep, the most recent figure standing at $94.6 million for Q1 2026.

• On a quarterly basis, Total Liabilities fell 23.93% year-over-year to $94.6 million in Q1 2026; TTM through Mar 2026 was $94.6 million, a 23.93% decrease from a year earlier, with the FY2025 full-year figure at $102.5 million, down 23.3% from the prior year.
• Total Liabilities retreated to $94.6 million in Q1 2026 per CCCC's latest filing, from $102.5 million in the prior quarter.
• Across five years, Total Liabilities topped out at $151.0 million in Q1 2022 and bottomed at $94.6 million in Q1 2026.
• The 5-year median for Total Liabilities is $133.6 million (2023), against an average of $129.5 million.
• Across the five-year window, Total Liabilities soared 36.86% in 2022 and declined 23.93% in 2026, its largest moves.
• Year by year, Total Liabilities stood at $141.6 million in 2022, then retreated by 7.96% to $130.3 million in 2023, then advanced by 2.52% to $133.6 million in 2024, then retreated by 23.3% to $102.5 million in 2025, then dropped by 7.68% to $94.6 million in 2026.
• Per Business Quant, the three latest CCCC Total Liabilities figures stand at $94.6 million (Q1 2026), $102.5 million (Q4 2025), and $111.1 million (Q3 2025).